Annovis Bio (ANVS) Consolidated Net Income (2019 - 2026)

Annovis Bio has reported Consolidated Net Income for 8 years, with the latest figure at -$18.1 million in Q1 2026.

• Quarterly Consolidated Net Income fell 196.4% year-over-year to -$18.1 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$42.3 million (down 33.56% YoY) and the FY2025 annual result came in at -$29.8 million, down 7.62% from the prior year.
• Consolidated Net Income retreated to -$18.1 million in Q1 2026 per ANVS's latest filing, from -$10.3 million in the prior quarter.
• Over five years, Consolidated Net Income peaked at -$1.1 million in Q1 2024 and troughed at -$22.2 million in Q4 2023.
• A 5-year average of -$9.2 million and a median of -$7.7 million in 2022 frame the typical range for Consolidated Net Income.
• The sharpest annual moves came in 2024 and 2025: Consolidated Net Income jumped 89.04% in 2024, then slumped 472.89% in 2025.
• Over 5 years, Consolidated Net Income stood at -$7.7 million in 2022, then tumbled by 187.51% to -$22.2 million in 2023, then soared by 64.38% to -$7.9 million in 2024, then tumbled by 30.38% to -$10.3 million in 2025, then tumbled by 75.63% to -$18.1 million in 2026.
• According to Business Quant data, Consolidated Net Income over the past three periods registered -$18.1 million, -$10.3 million, and -$7.5 million for Q1 2026, Q4 2025, and Q3 2025 respectively.